Cynata

Weekend cell biology reads: Mesoblast COVID-19 deal, pubs

bergert cell stem cell 2020 cell mechanics sm

The COVID-19 pandemic is tearing through the country right as we are starting into the holiday season, but the wheels of science including cell biology keep going and we keep reading all the great work. What news or papers caught your eye? Here are some of the things I have on my list of reading. …

Weekend cell biology reads: Mesoblast COVID-19 deal, pubs Read More »

Overview of IPS cell prospects for clinical impact

IPS-cell-clincial-trials-map

IPS cell research is a growing area of promise for regenerative medicine. These stem cells, also known as iPSCs or more formally as Induced Pluripotent Stem Cells, are engineered cells that are programmed to function the same way as embryonic stem cells. They can be differentiated into possibly any type of cell that is needed for …

Overview of IPS cell prospects for clinical impact Read More »

Stem cell good news on biotechs & cool new organoid paper

Pham-et-al.-2018

There’s some recent stem cell good news out there including new papers and biotech developments. The stem cell and regenerative medicine field is really diverse and runs the gamut from really worrying stuff to very exciting, legit developments. In this post, I’m going to focus on the encouraging recent developments. What do I see as …

Stem cell good news on biotechs & cool new organoid paper Read More »

Stem cell therapy review of good news: UC Davis, Asterias, Cynata, Mesoblast, ViaCyte

VC-01-post-implant-final1-e1503703572933

It’s a difficult, but very important road to conclusively prove that an investigational stem cell therapy is both safe and effective in order to get final approval FDA or equivalents in other countries. For this reason, it is beneficial to highlight even small, but positive steps forward including encouraging pre-clinical data. Today I’m doing a …

Stem cell therapy review of good news: UC Davis, Asterias, Cynata, Mesoblast, ViaCyte Read More »

Cynata stem cell trial update: CEO Ross Macdonald interview

Koch-et-al_2016_MCA-derived-MSC-Treatment-of-Hindlimb-Ischemia-in-Mice-e1498668676851

Stem cell clinical trials have a certain gravitational pull for me as I’m always fascinated by them and since the new Cynata trial is moving forward, I recently did an interview their CEO, Dr. Ross A. Macdonald to find out more. PK: Cynata’s recently initiated clinical trial aims to treat GVHD as have other stem …

Cynata stem cell trial update: CEO Ross Macdonald interview Read More »